Precision oncology programs turn on specific questions: whether a target is relevant in the disease context, whether a candidate reaches and engages it, and whether the biomarker strategy measures what the program assumes it measures.
Research areas
Where the evidence questions sit
Target and candidate biology
- Disease-relevant target biology and expression
- Molecular and antibody-based research on candidates
- Mechanism-of-action evidence and its limits
Biomarkers and in vivo evidence
- Biomarker evaluation for selection and response
- Suitable preclinical imaging for distribution and engagement
- PK/PD evidence interpreted alongside target biology
Value for R&D teams
For biotechnology and pharmaceutical R&D teams, the value is a clearer basis for the decisions that consume the most resources: which target to commit to, which candidate to advance, and which experiment will actually reduce uncertainty before the next stage of development.
Engagements connect to the translational evidence, molecular research, and imaging capabilities, individually or as an integrated program.
Boundary: Preclinical evidence informs development decisions; it does not predict clinical outcomes, and nothing on this page implies clinical-stage products or trials.
Have an oncology program question?
Tell us the target, the candidate stage, and the decision ahead.